Comment on: 'Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada', Wilson et al., 22 June 2018.
作者信息
McGirr Ashleigh, Iqbal Shehzad M, Olbrecht Jan, Varghese Lijoy
机构信息
GSK, Mississauga, ON, Canada.
GSK, Wavre, Belgium.
出版信息
Infect Dis Ther. 2018 Dec;7(4):535-538. doi: 10.1007/s40121-018-0220-3. Epub 2018 Nov 8.
Abstract
摘要
相似文献
1
Comment on: 'Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada', Wilson et al., 22 June 2018.评论：《加拿大13价肺炎球菌结合疫苗向10价肺炎球菌结合疫苗潜在转换对临床和经济的影响》，威尔逊等人，2018年6月22日。
Infect Dis Ther. 2018 Dec;7(4):535-538. doi: 10.1007/s40121-018-0220-3. Epub 2018 Nov 8.
2
Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.在新加坡，结合型肺炎球菌疫苗接种的成本效益：7 价、10 价和 13 价疫苗的比较估计。
Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.
3
Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.英国常规肺炎球菌疫苗接种的成本效益分析：使用马尔可夫模型对沛儿-10疫苗和13价肺炎球菌结合疫苗的比较
BMJ Open. 2016 Nov 30;6(11):e010776. doi: 10.1136/bmjopen-2015-010776.
4
Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.韩国儿童肺炎球菌结合疫苗（PHiD-CV）接种的成本效益分析。
Hum Vaccin Immunother. 2018 Jan 2;14(1):85-94. doi: 10.1080/21645515.2017.1362513. Epub 2017 Nov 8.
5
Estimated Annual Health and Cost Impact of PHiD-CV Immunization Program in Brazil.巴西 PHiD-CV 免疫计划的年度健康和成本影响预估。
Pediatr Infect Dis J. 2019 Oct;38(10):e260-e265. doi: 10.1097/INF.0000000000002436.
6
A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand.新西兰全民推广使用 10 价肺炎球菌-无荚膜流感嗜血杆菌蛋白 D 结合疫苗（PHiD-CV）与 13 价肺炎球菌结合疫苗（PCV13）的成本效益分析
Appl Health Econ Health Policy. 2018 Jun;16(3):331-345. doi: 10.1007/s40258-018-0387-5.
7
Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.10价肺炎球菌非分型流感嗜血杆菌蛋白D结合疫苗（PHiD-CV）对马里第二年儿童进行2剂补种疫苗接种的安全性、反应原性和免疫原性：一项开放性研究的结果
Hum Vaccin Immunother. 2015;11(9):2207-14. doi: 10.1080/21645515.2015.1016679.
8
Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.中国儿童用23价肺炎球菌多糖疫苗、7价肺炎球菌结合疫苗及预测中的13价肺炎球菌结合疫苗的成本效益与健康效益
Pediatr Infect Dis J. 2016 Nov;35(11):e353-e361. doi: 10.1097/INF.0000000000001288.
9
Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.在日本儿童中10价肺炎球菌非分型流感嗜血杆菌蛋白D结合疫苗（PHiD-CV）与白喉破伤风无细胞百日咳疫苗（DTPa）联合接种的免疫原性和安全性：一项随机对照研究。
Hum Vaccin Immunother. 2015;11(4):826-37. doi: 10.1080/21645515.2015.1012019.
10
Response to McGirr et al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada".对麦吉尔等人就《加拿大13价肺炎球菌结合疫苗转为10价肺炎球菌结合疫苗对婴儿接种的临床和经济影响》一文的评论的回应。
Infect Dis Ther. 2018 Dec;7(4):539-543. doi: 10.1007/s40121-018-0221-2. Epub 2018 Nov 8.
引用本文的文献
1
Comment on Gomez et. al. "Response to article by Wasserman et. al. (2018) 'Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico'".评论戈麦斯等人的文章“对 Wasserman 等人（2018 年）文章的回应：对墨西哥使用 13 价肺炎球菌结合疫苗替代 10 价疫苗的持续使用进行建模”。
Hum Vaccin Immunother. 2019;15(3):572-574. doi: 10.1080/21645515.2018.1558691. Epub 2019 Jan 18.
本文引用的文献
1
Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada.加拿大13价肺炎球菌结合疫苗转为10价肺炎球菌结合疫苗用于婴儿接种的潜在临床和经济影响
Infect Dis Ther. 2018 Sep;7(3):353-371. doi: 10.1007/s40121-018-0206-1. Epub 2018 Jun 22.
2
Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review.10价和13价肺炎球菌结合疫苗对拉丁美洲国家5岁以下儿童住院率和死亡率的影响及效果：一项系统评价
PLoS One. 2016 Dec 12;11(12):e0166736. doi: 10.1371/journal.pone.0166736. eCollection 2016.
3
Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.三种肺炎球菌结合疫苗预防加拿大魁北克侵袭性肺炎球菌疾病的有效性
Vaccine. 2015 May 28;33(23):2684-9. doi: 10.1016/j.vaccine.2015.04.005. Epub 2015 Apr 15.
4
Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children--a population-based study.十价肺炎球菌结合疫苗对芬兰儿童侵袭性肺炎球菌疾病的影响——一项基于人群的研究
PLoS One. 2015 Mar 17;10(3):e0120290. doi: 10.1371/journal.pone.0120290. eCollection 2015.
5
Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study.十价肺炎球菌结合疫苗在巴西预防侵袭性肺炎球菌病的效果：一项匹配病例对照研究。
Lancet Respir Med. 2014 Jun;2(6):464-71. doi: 10.1016/S2213-2600(14)70060-8. Epub 2014 Apr 10.
6
Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.模型参数估计和不确定性：ISPOR-SMDM 建模良好实践工作组的报告——6.
Value Health. 2012 Sep-Oct;15(6):835-42. doi: 10.1016/j.jval.2012.04.014.
7
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1.建立良好研究实践模型——概述：ISPOR-SMDM 建立良好研究实践工作组 1 的报告。
Med Decis Making. 2012 Sep-Oct;32(5):667-77. doi: 10.1177/0272989X12454577.
8
The potential cost-effectiveness of infant pneumococcal vaccines in Australia.澳大利亚婴幼儿肺炎球菌疫苗的潜在成本效益。
Vaccine. 2011 Oct 19;29(45):8077-85. doi: 10.1016/j.vaccine.2011.08.050. Epub 2011 Aug 22.
9
Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines.10 价和 13 价肺炎球菌结合疫苗的药物经济学评价。
Vaccine. 2010 Jul 26;28(33):5485-90. doi: 10.1016/j.vaccine.2010.05.058. Epub 2010 Jun 8.
Zotero 插件